A powerful reminder of scientific progress, patient rights and equal access in chronic myeloid leukemia (CML)

⚠️ Why Does It Matter?

CML once carried high mortality, but today tyrosine kinase inhibitors (TKIs) allow many patients to enjoy long lives with good quality of life . 22 Septembersymbolizes CML's defining genetic event, t(9;22) (the Philadelphia chromosome), highlighting both scientific breakthroughs and access and equity challenges.

🌍 The Origins and Aims of World CML Day

In 2008, patient communities launched the day; since 2011, it has been observed worldwide. Its aims include:

Global Awareness: Informing the public, policymakers and healthcare professionals
Patient and Family Support: Highlighting emotional, practical and social needs
Celebrating Scientific Progress: New treatments and monitoring strategies
Education and Advocacy: Drawing attention to symptoms, diagnosis, treatment and access/financial barriers
Strengthening the Global Voice: Centering the experiences of people living with CML

🧬 What Is CML? Symptoms and Treatment

Chronic Myeloid Leukemia (CML)is a chronic blood disorder in which bone marrow myeloid blood cells multiply uncontrollably. It belongs to the myeloproliferative neoplasm group. CML arises from the Philadelphia chromosome (t(9;22)(q34;q11)), a genetic alteration. This translocation creates the BCR::ABL1 fusion gene, producing a continuously active tyrosine kinase enzyme. This drives persistent division of bone marrow stem cells and disease development.

🩺 CML Symptoms

CML usually progresses slowly; during the chronic phase, many patients have no obvious symptoms. Progression or delayed diagnosis may produce:

Fatigue and Weakness: May reflect anemia and high white blood cell counts.
Weight Loss and Night Sweats: Classic signs of chronic leukemias.
Enlarged Spleen (Splenomegaly): May cause abdominal fullness and pain.
Abdominal Pain and Early Satiety: The enlarged spleen may press on the stomach.
Easy Bruising, Gum Bleeding: Related to platelet dysfunction or low counts.
Headache, Blurred Vision: May occur with very high leukocyte counts (hyperviscosity syndrome).

💊 CML Treatment Approaches

The discovery of tyrosine kinase inhibitors (TKIs)revolutionized CML treatment. They target BCR::ABL1 kinase to control disease molecularly. Strategies depend on disease phase, risk score and individual clinical characteristics:

First-Generation TKI: Imatinibtransformed CML treatment in 2001 and remains a first-line option for many patients.
Second-Generation TKIs: Dasatinib, Nilotinib, Bosutinib are preferred for high-risk patients or imatinib resistance/intolerance.
Third-Generation TKI: Ponatinibis particularly active against resistant mutations such as T315I .
Supportive Treatments: Hydroxyurea or leukapheresis may initially reduce very high white blood cell counts.
Allogeneic Stem Cell Transplantation: Now uncommon; considered for highly resistant disease or progression to blast crisis.

During treatment, molecular monitoring (BCR::ABL1 levels by PCR), side effect management and individualized dose adjustments are crucial.

📊 CML in Numbers: A Treatment Transformation

5–10-Year Survival: With modern TKIs, ≈85–95%.
Deep Molecular Response (DMR): The proportion achieving MR4/MR4.5 reaches 60%+ at 5 years.
Treatment-Free Remission (TFR): Among suitable patients, 40–50% may be monitored without TKIs.
Quality of Life: Once-daily treatments support participation in work and social life.

Note: Rates vary with patient characteristics, risk score and adherence.

🚧 Ongoing Challenges

Access and Equity

Between countries and regions, access to drugs, monitoring tests and specialists can differ.

Financial Burden

Long-term treatment and molecular monitoring can burden household budgets and healthcare systems .

Stigma and Psychosocial Effects

Chronic cancer can create invisible barriers in work and social life; psychosocial support is important.

Seeking a Cure & Optimizing TFR

Who should stop TKIs, when and how? There remains a need for standardization and biomarkers to improve prediction .

🤝 Stronger Together

Healthcare Professionals: Guideline-based diagnosis/treatment and regular molecular monitoring
Governments/Payers: Equitable access through sustainable reimbursement and supply chains
Pharmaceutical Companies: Innovative treatment development, access programs
Patients & Families: Adherence, appointment/test follow-up, psychosocial solidarity
Public & Media: Accurate information, stigma-reducing language and advocacy

🧭 Quick Summary

Date: 22 September (symbolically linked to t(9;22))
Scientific Basis: BCR::ABL1 kinase activity
Breakthrough: TKIs bring 5–10-year survival to ≈ 85–95%
DMR & TFR: In suitable patients, TFR is maintained in ~40–50% for 1–2 years without treatment.
Priorities: Access/equity, financial sustainability, personalized TFR strategies

🚀 A Call to Action

This 22 September, spread awarenessand show solidarity with people living with CML. Education, advocacy and solidarity can create a more equitable, hopeful future.